155 related articles for article (PubMed ID: 1536960)
1. An animal model of allogeneic donor platelet refractoriness: the effect of the time of leukodepletion.
Blajchman MA; Bardossy L; Carmen RA; Goldman M; Heddle NM; Singal DP
Blood; 1992 Mar; 79(5):1371-5. PubMed ID: 1536960
[TBL] [Abstract][Full Text] [Related]
2. Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion.
Bordin JO; Bardossy L; Blajchman MA
Blood; 1994 Jul; 84(1):344-8. PubMed ID: 8018929
[TBL] [Abstract][Full Text] [Related]
3. Experimental animal model of refractoriness to donor platelets: the effect of plasma removal and the extent of white cell reduction on allogeneic alloimmunization.
Bordin JO; Bardossy L; Blajchman MA
Transfusion; 1993 Oct; 33(10):798-801. PubMed ID: 8236419
[TBL] [Abstract][Full Text] [Related]
4. The effect of leukodepletion on allogeneic donor platelet survival and refractoriness in an animal model.
Blajchman MA
Semin Hematol; 1991 Jul; 28(3 Suppl 5):14-7. PubMed ID: 1925637
[No Abstract] [Full Text] [Related]
5. Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions.
Pruss A; Kalus U; Radtke H; Koscielny J; Baumann-Baretti B; Balzer D; Dörner T; Salama A; Kiesewetter H
Transfus Apher Sci; 2004 Feb; 30(1):41-6. PubMed ID: 14746820
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
Novotny VM; van Doorn R; Witvliet MD; Claas FH; Brand A
Blood; 1995 Apr; 85(7):1736-41. PubMed ID: 7703481
[TBL] [Abstract][Full Text] [Related]
7. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
Trial to Reduce Alloimmunization to Platelets Study Group
N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
[TBL] [Abstract][Full Text] [Related]
8. Benefit of prestorage leukocyte depletion of single-donor platelet concentrates.
Chalandon Y; Mermillod B; Beris P; Doucet A; Chapuis B; Roux-Lombard P; Dayer JM
Vox Sang; 1999; 76(1):27-37. PubMed ID: 9933851
[TBL] [Abstract][Full Text] [Related]
9. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.
Sintnicolaas K; van Marwijk Kooij M; van Prooijen HC; van Dijk BA; van Putten WL; Claas FH; Novotny VM; Brand A
Blood; 1995 Feb; 85(3):824-8. PubMed ID: 7833483
[TBL] [Abstract][Full Text] [Related]
10. Determination
Thuku NW; Shikuku K; Mbugua A
Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
[TBL] [Abstract][Full Text] [Related]
11. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.
Seftel MD; Growe GH; Petraszko T; Benny WB; Le A; Lee CY; Spinelli JJ; Sutherland HJ; Tsang P; Hogge DE
Blood; 2004 Jan; 103(1):333-9. PubMed ID: 12958065
[TBL] [Abstract][Full Text] [Related]
12. Biologic effects of leukocytes present in transfused cellular blood products.
Bordin JO; Heddle NM; Blajchman MA
Blood; 1994 Sep; 84(6):1703-21. PubMed ID: 8080981
[TBL] [Abstract][Full Text] [Related]
13. Effects on recipients of exposure to allogeneic donor leukocytes.
Dzik WH
J Clin Apher; 1994; 9(2):135-8. PubMed ID: 7798162
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of different methods of leukoreduction of donor platelets to prevent alloimmune platelet refractoriness and induce tolerance in a canine transfusion model.
Slichter SJ; Fish D; Abrams VK; Gaur L; Nelson K; Bolgiano D
Blood; 2005 Jan; 105(2):847-54. PubMed ID: 15231575
[TBL] [Abstract][Full Text] [Related]
15. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
[TBL] [Abstract][Full Text] [Related]
16. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
Hitzler WE
Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
[TBL] [Abstract][Full Text] [Related]
17. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
[TBL] [Abstract][Full Text] [Related]
18. Use of leukodepletion filters for the removal of bacteria.
Dzik W
Immunol Invest; 1995; 24(1-2):95-115. PubMed ID: 7713609
[TBL] [Abstract][Full Text] [Related]
19. Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model.
Slichter SJ; Pellham E; Bailey SL; Christoffel T; Gettinger I; Gaur L; Latchman Y; Nelson K; Bolgiano D
Blood; 2017 Aug; 130(8):1052-1061. PubMed ID: 28705838
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets.
Heddle NM; Klama L; Meyer R; Walker I; Boshkov L; Roberts R; Chambers S; Podlosky L; O'Hoski P; Levine M
Transfusion; 1999 Mar; 39(3):231-8. PubMed ID: 10204584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
